Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Available 1Active not recruiting 1

Sponsor Class

INDUSTRY 3NIH 2OTHER 1

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1Sarcoma 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Sarcoma 1Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1

Interventions

pembrolizumab 610Carboplatin 375Paclitaxel 283Cisplatin 268Gemcitabine 256Pemetrexed 194Bevacizumab 191Nivolumab 190Docetaxel 190Injections 169Cyclophosphamide 148atezolizumab 138Capecitabine 134Fluorouracil 133Oxaliplatin 132Dexamethasone 129Fulvestrant 115durvalumab 114130-nm albumin-bound paclitaxel 111fludarabine 102Cetuximab 101Leucovorin 97Rituximab 96venetoclax 90Lenalidomide 84Prednisone 79enzalutamide 78Azacitidine 76Irinotecan 74Ipilimumab 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × LY3023414 × 1 year × Clear all
NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Eli Lilly and Company

Phase 1 Active not recruiting
198 enrolled
Breast

Breast Neoplasms

NCT02632994 2025-09-29

Master Rollover Protocol for Continued Safety Assessment of Study Drug

Eli Lilly and Company

Available
Tumor-Agnostic

Neoplasms

NCT02784795 2025-08-21

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
94 enrolled 28 charts
BreastGastrointestinalSarcoma

Breast Neoplasms, Colonic Neoplasms, Sarcoma, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡